The panelists share their insights on risk assessment, and customized treatment strategies for high-risk NMIBC. The panelists discuss the evolving landscape of bladder cancer treatments, focusing on balancing bladder-sparing therapies. The panelists debate the potential of combining intravesical immunotherapy with immune checkpoint inhibitors. The panelists share their perspectives on SunRISe-1 and the evolving role of TAR-200 in treating BCG-unresponsive UC. The second segment of this roundtable focuses on the evolving landscape of treatments for BCG-unresponsive bladder cancer. Part one of this roundtable highlights current practices, emerging therapies, and the future landscape of NMIBC care. The panel explores the distinct roles of alpha and beta emitters in radiopharmaceutical therapy for prostate cancer care. The expert panel discusses emerging biomarkers and treatment combinations for CRPC and mHSPC. The evolving role of RLT and radium-223 in managing metastatic mHSPC and CRPC is discussed. The panel examines the impact of the latest data from ARANOTE and PEACE-3 in part three of this roundtable. The panelists discuss key considerations for patient selection in doublet and triplet therapies for mHSPC and CRPC. In part one of this roundtable, the panel discusses advances in imaging and tailored treatment strategies for prostate cancer In the final segment of the roundtable, the panel debates the real-world integration of new therapies into everyday practice. In part five of this NMIBC roundtable, the panelists discuss integrating new therapies such as TAR-200 into clinical practice Part four of this roundtable series examines the SunRISe-1 trial results for high-risk NMIBC. The panelists discuss advancements in NMIBC treatment in part three of this roundtable, including pembrolizumab and TAR-200. Part two of this roundtable explores intravesical and systemic therapies, and the importance of accurate risk stratification. The first part of this roundtable focuses on recent trial data, the role of TUR quality, and precision medicine for NMIBC. The panelists discuss promising new advancements and novel therapies for treating RCC, including LAG-3 and CAR-T therapies. The panel discusses how designing effective trials could refine the approach to treatment strategies for RCC.